

Last Name:	First Name:	Middle Initial:
DOB:	Street Address:	
Medical School:	City:	
Cell Phone:	State:	
Primary Email:	ZIP Code:	
Student ID:		

Option 1	Vaccine	Date				
MMR	MMR Dose #1					
-2 doses of MMR vaccine	MMR Dose #2					
Option 2	Vaccine or Test	Date				
	Measles Vaccine Dose #1		Serology Results			
Measles -2 doses of vaccine or positive serology	Measles Vaccine Dose #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
podlavo daralogy	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
	Mumps Vaccine Dose #1		Serology Results			
Mumps -2 doses of vaccine or positive serology	Mumps Vaccine Dose #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
			S	erology Results		
Rubella -1 dose of vaccine or	Rubella Vaccine		Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
Tetanus-diphtheria-per	tussis – One (1) dose of adult Tdap. If last Tdap is mo	re than 10 years old, pro	vide dates o	flast Td and Tdap		
	Tdap Vaccine (Adacel, Boostrix, etc)					
	Td Vaccine (if more than 10 years since last Tdap)					
Varicella (Chicken Pox)	- 2 doses of vaccine or positive serology					
	Varicella Vaccine #1		S	Serology Results		
	Varicella Vaccine #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
	Serologic Immunity (IgG antibody titer)	IU/ml				
Influenza Vaccine - 1 do.	se annually each fall					
5		Date				
Date of last dose	Flu Vaccine					
COVID-19 Vaccine - prin	nary series of two (2) doses and booster dose	Date	Comp	oany or Trade Name		
	COVID-19 Vaccine #1					
	COVID-19 Vaccine #2					
			•			



ame:		Da	ite of Birth:		
(La	st, First, Middle Initial)	_	1)	mm/dd/yyyy)	
by a <b>QUANTITATIVE</b> Hepatite If the test result is negative, re	on - 3 doses of Engerix-B, PreHevbrio, Recombivax of is B Surface Antibody test drawn 4-8 weeks after last opeat another Hepatitis B vaccine series followed by a sine series, a "non-responder" status is assigned. Se	vaccine dose. A test tite repeat test titer. If the F	r <u>&gt;</u> 10mIU/mL is positiv Iepatitis B Surface Ant	e for immunity. ibodv test is	Copy Attached
	3-dose vaccines (Energix-B, PreHevbrio, Recombivax, Twinrix) or 2-dose vaccine (Heplisav-B)	3 Dose Series	2 Dose Series		
Primary Hepatitis B Series	Hepatitis B Vaccine Dose #1				
Heplisav-B only requires two	Hepatitis B Vaccine Dose #2				
doses of vaccine followed by antibody testing	Hepatitis B Vaccine Dose #3				
	<b>QUANTITATIVE</b> Hep B Surface Antibody Test	mIU/mI		I	
Repeat		3 Dose Series	2 Dose Series		
Hepatitis B Series	Hepatitis B Vaccine Dose #4				
Only If no response to primary series	Hepatitis B Vaccine Dose #5				
Heplisav-B only requires two doses of vaccine followed by	Hepatitis B Vaccine Dose #6				
antibody testing	<b>QUANTITATIVE</b> Hep B Surface Antibody Test		mIU/ml		
Hepatitis B Vaccine Non-responder	If the Hepatitis B Surface Antibody test primary and repeat vaccine series, vaccevaluated appropriately. Certain instituti of non-responder status" document before	cine non-responder ons may request si	s should be coun gning an "acknow	seled and	
	Additional Document	tation			
include meningitis vaccine	ove additional requirements depending upon rowhich is mandated in some states if you live in expounding proof of expounding proof of the provide provid	dormitory style housi	ng. If you will be pai	ticipating in	
Vaccination, Test or E	xamination	Date	Result or Inte	rpretation	
Physical Exam (if require	ed)				



Name:		Date of Birth:	
<del>-</del>	(Last, First, Middle Initial)	-	(mm/dd/yyyy)

**TUBERCULOSIS (TB) SCREENING** – All U.S. healthcare personnel are screened pre-placement for TB. Results of the last (2) TB Skin Tests (TSTs)) or (1) IGRA blood test are required <u>regardless</u> of prior BCG status. The 2-step TST protocol must have been placed within the past 12 months prior to clinical duties, and must have been performed in the U.S. The second TST must be placed at least 1 week after the first TST read date. If you have a history of a positive TST (PPD)>10mm or a positive IGRA blood test, please supply information regarding any evaluation and/or treatment below. You only need to complete ONE section, A or B.

# Skin test or IGRA results should not expire during proposed elective rotation dates or must be updated with the receiving institution prior to rotation.

		must be upa			n prior to rotation.	
			Tuberculosis S	creening Histo	ry	
	Section A		Date Placed	Date Read	Result	Interpretation
e complete only one TB section based on your history	History of Negative TB Skin	TST #1			mm	□ Pos □ Neg □ Equiv
		TST #2			mm	□ Pos □ Neg □ Equiv
	Test or Blood Test					
5				Date	Result	
, y c	T-spots or QuantiFERON TB Gold blood tests for	QuantiFERON TB (Interferon Gamma Relea	Gold or T-Spot asing Assay)		☐ Positive ☐ Ne	gative
5	tuberculosis  Use additional rows as needed	QuantiFERON TB (Interferon Gamma Relea	Gold or T-Spot asing Assay)		☐ Positive ☐ Ne	gative
ase.	.000 00 1100000					
Ž						
ב כ	Section B		Date Placed	Date Read	Result	
סמכ		Positive TST			mm	
מ				Date	Result	
<u>ם</u>	History of	QuantiFERON TB Gold or T-Spot (Interferon Gamma Releasing Assay)			□ Positive □ N	legative
( OI	Positive Skin Test or	Chest X-ray*			*Provide docume	ntation or result
	Positive Blood Test	Positive Blood			☐ Yes ☐ No	
ete						
mpi						
00		Date of Last Annual TB Symptom Questionnaire				
3SE						
Piease						



		Date (	of Birth:
(Last, First, N	/liddle Initial)		(mm/dd/yyyy)
	Additi	onal Information	
	Addition	onai information	
Healthcare Professional	SIGNED BY A LICENSE	D HEALTHCARE PRO	OFESSIONAL OR DESIGNEE:
Signature:			Date:
Printed Name:			Office Use Only
Title:			
Address Line 1:			
Address Line 2:			
City:			
State:			
Zip:			
Phone:		F4.	$\neg$
		Ext:	<u>-</u>
Fax:		Ext:	

#### \*Sources:

- 1. <u>Hepatitis B In: Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds.</u> 13th ed. Washington D.C. Public Health Foundation, 2015
- 2. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, Vol 60(7):1-45
- 3. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, MMWR, Vol 62(RR10):1-19
- 4. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Vol 67(1):1-31
- 5. Sosa LE, Nijie GL, Lobato MN, et.al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from National Tuberculosis Controllers Association and CDC, 2019. MMWR2019;68:439-443. https://www.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm?s cid+mm6819a3 w